Niraparib in Metastatic Pancreatic Cancer After Previous Chemotherapy (NIRA-PANC): a Phase 2 Trial

Summary

The goal of this clinical research study is to learn if Niraparib can help to control metastatic pancreatic cancer. The safety of this drug will also be studied. Niraparib is FDA approved and commercially available for the treatment of ovarian cancer. Its use in this study is investigational.

Timeline

Start

2019-01-22

Primary completion

2023-04-25

Completion

2025-02-01

Publications

• Kasi A, Al-Rajabi RMT, Baranda JC, Saeed A, Dai J, Chalise P, Weir S, Sear B, Carroll E, Bradbury S, Tripathi A, Hyter S, Beeki V, McKittrick RJ, Kumer S, Schmitt T, Soper S, Godwin AK, Sun W. Niraparib in pancreatic cancer with germline or somatic DNA damage repair (DDR) gene alterations (BRCA and beyond): A phase II study (NIRA-PANC). Oncologist. 2026 Jun 5:oyag225. doi: 10.1093/oncolo/oyag225. Online ahead of print.
• Freed IM, Kasi A, Fateru O, Hu M, Gonzalez P, Weatherington N, Pathak H, Hyter S, Sun W, Al-Rajabi R, Baranda J, Hupert ML, Chalise P, Godwin AK, A Witek M, Soper SA. Circulating Tumor Cell Subpopulations Predict Treatment Outcome in Pancreatic Ductal Adenocarcinoma (PDAC) Patients. Cells. 2023 Sep 13;12(18):2266. doi: 10.3390/cells12182266.

Drugs

Indications